<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04084041</url>
  </required_header>
  <id_info>
    <org_study_id>HOMECARE_CF</org_study_id>
    <nct_id>NCT04084041</nct_id>
  </id_info>
  <brief_title>Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis</brief_title>
  <official_title>Efficacy of the Simeox Airway Clearance Technology in the Treatment of Children With Clinically Stable Cystic Fibrosis- Cross-over Study With Randomization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Physio-Assist</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Physio-Assist</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chest physiotherapy plays a crucial role in treatment of lung disease in cystic fibrosis
      (CF). New airway clearance techniques (ACTs) adapted to individual needs are still being
      sought to achieve the best effect of airway clearance. The primary aim of this study is to
      assess the efficacy of a new ACT (Simeox) on pulmonary function in children with CF. 40 CF
      patients with stable respiratory function will be randomized 1:1 to Simeox or conventional
      chest physiotherapy (CCPT) therapy (control group) and treated at home during 1 month. After
      a short washout period, patients will be treated at home onto the alternative treatment for 1
      month (crossover design). Lung function, quality of life, pulmonary exacerbation and safety
      will be evaluated at 1 month for each therapy period.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total lung resistance</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of R5hz - Impulse Oscillometry (IOS) from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in central lung resistance</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of R20hz - Impulse Oscillometry (IOS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in peripheral lung resistance</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of R5-20hz - Impulse Oscillometry (IOS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total lung reactance</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of X5hz -Impulse Oscillometry (IOS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in area of reactance (AX)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of AX -Impulse Oscillometry (IOS) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total score of Cystic Fibrosis Questionnaire-Revised (CFQ-R)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of CFQ-R total score (0-100) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in respiratory domain score of Cystic Fibrosis Questionnaire Revised (CFQ-R) questionnaire</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of respiratory score (0-100) of CFQ-R from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Expiratory Volume in 1 second (FEV1)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of FEV1 (spirometry) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Forced Vital Capacity (FVC)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of FVC (spirometry) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Residual Volume (RV)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of RV (body plethysmography) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Maximal Expiratory Flow (MEF) at 25, 50 and 75% of expired volume</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of MEF 25, 50 and 75 (spirometry) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Mid Expiratory Flow (MMEF)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of MMEF (spirometry) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lung clearance index (LCI)</measure>
    <time_frame>1 month</time_frame>
    <description>Evolution of LCI with Nitrogen multiple breath washout (N2MBW) tests from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary exacerbation</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of pulmonary exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of adverse events related or not related to intervention</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cystic Fibrosis in Children</condition>
  <condition>Airway Clearance Impairment</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional chest physiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Simeox</intervention_name>
    <description>Airway clearance device</description>
    <arm_group_label>Conventional chest physiotherapy</arm_group_label>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CCPT</intervention_name>
    <description>Conventional chest physiotherapy</description>
    <arm_group_label>Conventional chest physiotherapy</arm_group_label>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject and his or her legally appointed and authorized representative will agree for
             treatment with Simeox technology

          -  willing and able to cooperate and learn new technic of drainage.

          -  age 8-18 years, on the date of admission to hospital.

          -  confirmed diagnosis of CF as determined by the investigator.

          -  able to perform pulmonary tests

        Exclusion Criteria:

        History of any illness or any clinical condition that, in the opinion of the investigator,
        might confound the cooperation or the results of the study or pose an additional risk to
        the subject in using study technology. This includes, but is not limited to, the following:

          -  contraindications to bronchial chest physiotherapy

          -  hemoptysis

          -  pneumothorax

          -  heart disease

          -  recent chest surgery

          -  recent chest injury

          -  history of lung transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorota Sands, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IMiD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent MORIN, MD, PhD</last_name>
    <phone>0603273012</phone>
    <phone_ext>+33</phone_ext>
    <email>morin@physio-assist.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IMiD</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorota SANDS, MD, PhD</last_name>
      <phone>22 32 77 371</phone>
      <phone_ext>+48</phone_ext>
      <email>dorota.sands@imid.med.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Airway clearance technique</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

